Startseite>>EGFRvIII Peptide (trifluoroacetate salt)

EGFRvIII Peptide (trifluoroacetate salt)

Katalog-Nr.GC91027

Ein EGFRvIII-Peptidfragment

Products are for research use only. Not for human use. We do not sell to patients.

EGFRvIII Peptide (trifluoroacetate salt) Chemische Struktur

Größe Preis Lagerbestand Menge
1 mg
36,00 $
Auf Lager
5 mg
163,00 $
Auf Lager
10 mg
288,00 $
Auf Lager
25 mg
632,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

EGFRvIII peptide is a synthetic peptide that corresponds to the fusion junction of EGFRvIII, a tumor-specific, constitutively active variant of EGFR that lacks amino acids 6-273 of wild-type EGFR.1,2 It binds to MHC class I subtype HLA-A*0201-positive T2 cells when used at a concentration of 25 µg/ml.1 EGFRvIII peptide induces antigen presentation in dendritic cells derived from isolated human peripheral blood mononuclear cells (PBMCs), which stimulates activation of, and IFN-γ production by, CD8+ cytotoxic T lymphocytes. Immunization with EGFRvIII peptide (15 µg/animal), in combination with the toll-like receptor 5 (TLR5) agonist flagellin B, increases the number of CD8+ T cells and decreases the number of regulatory T cells (Tregs) in the brain, reduces tumor volume, and increases survival rate in an orthotopic GL261 glioblastoma mouse xenograft model.2

Bewertungen

Review for EGFRvIII Peptide (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for EGFRvIII Peptide (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.